| Talimogene laherparepvec improves durable response rate in patients with advanced melanoma RHI Andtbacka, HL Kaufman, F Collichio, T Amatruda, N Senzer, ... Journal of clinical oncology 33 (25), 2780-2788, 2015 | 2569 | 2015 |
| Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group I Puzanov, A Diab, K Abdallah, CO Bingham, C Brogdon, R Dadu, ... Journal for immunotherapy of cancer 5, 1-28, 2017 | 1684 | 2017 |
| Oncolytic viruses: a new class of immunotherapy drugs HL Kaufman, FJ Kohlhapp, A Zloza Nature reviews Drug discovery 14 (9), 642-662, 2015 | 1495 | 2015 |
| Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial HL Kaufman, J Russell, O Hamid, S Bhatia, P Terheyden, SP D'Angelo, ... The lancet oncology 17 (10), 1374-1385, 2016 | 1277 | 2016 |
| gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma DJ Schwartzentruber, DH Lawson, JM Richards, RM Conry, DM Miller, ... New England Journal of Medicine 364 (22), 2119-2127, 2011 | 1086 | 2011 |
| Consensus guidelines for the definition, detection and interpretation of immunogenic cell death L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ... Journal for immunotherapy of cancer 8 (1), 2020 | 769 | 2020 |
| Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma NN Senzer, HL Kaufman, T Amatruda, M Nemunaitis, T Reid, G Daniels, ... Journal of Clinical Oncology 27 (34), 5763, 2009 | 709 | 2009 |
| Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ... JAMA oncology 2 (2), 234-240, 2016 | 617 | 2016 |
| Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma HL Kaufman, DW Kim, G DeRaffele, J Mitcham, RS Coffin, S Kim-Schulze Annals of surgical oncology 17, 718-730, 2010 | 579 | 2010 |
| Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with … J Chesney, I Puzanov, F Collichio, P Singh, MM Milhem, J Glaspy, ... Journal of clinical oncology 36 (17), 1658, 2018 | 572 | 2018 |
| Integrating oncolytic viruses in combination cancer immunotherapy PK Bommareddy, M Shettigar, HL Kaufman Nature Reviews Immunology 18 (8), 498-513, 2018 | 548 | 2018 |
| Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma I Puzanov, MM Milhem, D Minor, O Hamid, A Li, L Chen, M Chastain, ... Journal of Clinical Oncology 34 (22), 2619, 2016 | 541 | 2016 |
| Characterization of CD4CD25 regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma GC Cesana, G DeRaffele, S Cohen, D Moroziewicz, J Mitcham, ... J Clin Oncol 24 (7), 1169-1177, 2006 | 427 | 2006 |
| Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7. 1 co-stimulatory molecule H Hörig, DS Lee, W Conkright, J Divito, H Hasson, M LaMare, A Rivera, ... Cancer Immunology, Immunotherapy 49, 504-514, 2000 | 403 | 2000 |
| Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial SP D’Angelo, J Russell, C Lebbé, B Chmielowski, T Gambichler, JJ Grob, ... JAMA oncology 4 (9), e180077-e180077, 2018 | 394 | 2018 |
| Comparison of RNA-seq and microarray-based models for clinical endpoint prediction W Zhang, Y Yu, F Hertwig, J Thierry-Mieg, W Zhang, D Thierry-Mieg, ... Genome biology 16, 1-12, 2015 | 394 | 2015 |
| Combination immunotherapy: a road map PA Ott, FS Hodi, HL Kaufman, JM Wigginton, JD Wolchok Journal for immunotherapy of cancer 5, 1-15, 2017 | 368 | 2017 |
| Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy H Rehman, AW Silk, MP Kane, HL Kaufman Journal for immunotherapy of cancer 4, 1-8, 2016 | 368 | 2016 |
| Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer JM Mehnert, A Panda, H Zhong, K Hirshfield, S Damare, K Lane, L Sokol, ... The Journal of clinical investigation 126 (6), 2334-2340, 2016 | 361 | 2016 |
| Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma RHI Andtbacka, F Collichio, KJ Harrington, MR Middleton, G Downey, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 328 | 2019 |
